5 days ago
Kepler Capital Sticks to Their Buy Rating for Novartis AG (NOVN)
Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on July 14 and set a price target of CHF106.00. The company's shares closed yesterday at CHF96.06.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Evans is a 2-star analyst with an average return of 0.1% and a 55.72% success rate. Evans covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novartis AG, and Novo Nordisk.
Novartis AG has an analyst consensus of Moderate Buy, with a price target consensus of CHF102.20, a 6.39% upside from current levels. In a report released on July 4, Deutsche Bank also maintained a Buy rating on the stock with a CHF115.00 price target.
Based on Novartis AG's latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of CHF13.62 billion and a net profit of CHF3.61 billion. In comparison, last year the company earned a revenue of CHF12.12 billion and had a net profit of CHF2.69 billion
